At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 144 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration·interventional·Posted Nov 25, 2014·Updated Sep 29, 2020
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Soft Tissue Sarcoma and Bone Sarcoma. Completed, enrolled 144 participants across 12 sites.
Detailed Summary
The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcoma, Bone Sarcoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartMar 2015
Primary CompletionJul 2020
TodayJul 2026
First PostedNov 25, 2014
Enrollment StartMar 1, 2015
Primary CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 11.6 years ago
Interventions
Pembrolizumabdrug